News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
860,113 Results
Type
Article (87381)
Company Profile (759)
Press Release (771947)
Multimedia
Podcasts (169)
Webinars (27)
Section
Business (233035)
Career Advice (4137)
Deals (39790)
Drug Delivery (134)
Drug Development (91237)
Employer Resources (202)
FDA (18274)
Job Trends (17396)
News (397342)
Policy (39923)
Tag
Academia (3003)
Academic (2)
Accelerated approval (18)
Adcomms (35)
Allergies (123)
Alliances (56979)
ALS (143)
Alzheimer's disease (1676)
Antibody-drug conjugate (ADC) (223)
Approvals (18286)
Artificial intelligence (479)
Autoimmune disease (68)
Automation (25)
Bankruptcy (406)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (158)
Biotechnology (484)
Bladder cancer (122)
Brain cancer (52)
Breast cancer (474)
Cancer (3773)
Cardiovascular disease (333)
Career advice (3553)
Career pathing (37)
CAR-T (241)
CDC (55)
Cell therapy (671)
Cervical cancer (32)
Clinical research (75258)
Collaboration (1358)
Company closure (4)
Compensation (922)
Complete response letters (59)
COVID-19 (2951)
CRISPR (81)
C-suite (567)
Cystic fibrosis (132)
Data (4214)
Decentralized trials (2)
Denatured (60)
Depression (109)
Diabetes (444)
Diagnostics (7083)
Digital health (36)
Diversity (11)
Diversity, equity & inclusion (49)
Drug discovery (229)
Drug pricing (186)
Drug shortages (36)
Duchenne muscular dystrophy (199)
Earnings (98742)
Editorial (54)
Employer branding (25)
Employer resources (171)
Events (132759)
Executive appointments (978)
FDA (20669)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (5)
Frontotemporal dementia (14)
Funding (1226)
Gene editing (173)
Generative AI (46)
Gene therapy (538)
GLP-1 (1011)
Government (5376)
Grass and pollen (7)
Guidances (336)
Healthcare (20937)
HIV (48)
Huntington's disease (37)
IgA nephropathy (55)
Immunology and inflammation (238)
Immuno-oncology (19)
Indications (51)
Infectious disease (3183)
Inflammatory bowel disease (184)
Inflation Reduction Act (15)
Influenza (93)
Intellectual property (184)
Interviews (815)
IPO (17925)
IRA (59)
Job creations (5196)
Job search strategy (2864)
Kidney cancer (15)
Labor market (74)
Layoffs (636)
Leadership (32)
Legal (10148)
Liver cancer (91)
Longevity (12)
Lung cancer (537)
Lymphoma (258)
Machine learning (28)
Management (66)
Manufacturing (626)
MASH (136)
Medical device (14856)
Medtech (14877)
Mergers & acquisitions (22730)
Metabolic disorders (1137)
Multiple sclerosis (137)
NASH (23)
Neurodegenerative disease (224)
Neuropsychiatric disorders (59)
Neuroscience (2692)
NextGen: Class of 2025 (7687)
Non-profit (5095)
Now hiring (57)
Obesity (554)
Opinion (310)
Ovarian cancer (123)
Pain (161)
Pancreatic cancer (165)
Parkinson's disease (239)
Partnered (28)
Patents (410)
Patient recruitment (297)
Peanut (57)
People (66214)
Pharmaceutical (144)
Pharmacy benefit managers (26)
Phase I (23200)
Phase II (32683)
Phase III (24586)
Pipeline (2644)
Policy (292)
Postmarket research (3554)
Preclinical (10479)
Press Release (72)
Prostate cancer (192)
Psychedelics (51)
Radiopharmaceuticals (282)
Rare diseases (651)
Real estate (7421)
Recruiting (78)
Regulatory (27927)
Reports (64)
Research institute (2688)
Resumes & cover letters (650)
Rett syndrome (15)
RNA editing (15)
RSV (70)
Schizophrenia (133)
Series A (204)
Series B (150)
Service/supplier (30)
Sickle cell disease (79)
Special edition (25)
Spinal muscular atrophy (170)
Sponsored (40)
Startups (4318)
State (2)
Stomach cancer (17)
Supply chain (99)
Tariffs (93)
The Weekly (107)
Vaccines (1036)
Venture capital (66)
Weight loss (391)
Women's health (58)
Worklife (21)
Date
Today (3)
Last 7 days (570)
Last 30 days (2252)
Last 365 days (33453)
2025 (25652)
2024 (38139)
2023 (42568)
2022 (53929)
2021 (58724)
2020 (57666)
2019 (51338)
2018 (39124)
2017 (37190)
2016 (38330)
2015 (44433)
2014 (39673)
2013 (36268)
2012 (38416)
2011 (38383)
2010 (39616)
Location
Africa (1279)
Alabama (80)
Alaska (7)
Arizona (302)
Arkansas (14)
Asia (50906)
Australia (8948)
California (9297)
Canada (2821)
China (874)
Colorado (395)
Connecticut (413)
Delaware (257)
Europe (116990)
Florida (1368)
Georgia (311)
Hawaii (3)
Idaho (67)
Illinois (802)
India (49)
Indiana (452)
Iowa (19)
Japan (310)
Kansas (123)
Kentucky (38)
Louisiana (20)
Maine (77)
Maryland (1259)
Massachusetts (6991)
Michigan (307)
Minnesota (558)
Mississippi (4)
Missouri (117)
Montana (33)
Nebraska (26)
Nevada (106)
New Hampshire (76)
New Jersey (2565)
New Mexico (32)
New York (2538)
North Carolina (1399)
North Dakota (10)
Northern California (4181)
Ohio (291)
Oklahoma (21)
Oregon (50)
Pennsylvania (1935)
Puerto Rico (19)
Rhode Island (46)
South America (1655)
South Carolina (46)
South Dakota (1)
Southern California (3553)
Tennessee (149)
Texas (1456)
United States (34396)
Utah (275)
Virginia (245)
Washington D.C. (83)
Washington State (802)
West Virginia (4)
Wisconsin (96)
Wyoming (1)
There are 860,113 results that match your search.
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Can AI Clinical Trial Technology Deliver on Its Promise?
To drive true innovation in drug development, executives must not let excitement about the latest shiny object obscure ultimate outcomes.
October 13, 2025
·
4 min read
·
Jason Housley
FDA
Consistency in the Chaos: FDA Approvals Within Average Range as Q4 Kicks Off
Heading into the final quarter of a year that has seen dramatic upheaval at the FDA—from the exodus of numerous senior leaders to unclear policy changes and a safety saga that engulfed the gene therapy space—drug approvals appear roughly on par with recent years.
October 13, 2025
·
4 min read
·
Heather McKenzie
Rare Diseases
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause
Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease.
October 13, 2025
·
7 min read
·
Tristan Manalac
Press Releases
PreveCeutical Announces Results from Annual General and Special Meeting and Increase to Size of Non-Brokered Private Placement
October 10, 2025
·
5 min read
Drug pricing
AstraZeneca Becomes Second Pharma to Strike DTC Deal With Trump Administration
The British pharmaceutical giant has joined the direct-to-consumer push, following Pfizer and Amgen’s announcements in response to the president’s calls to lower U.S. drug prices.
October 10, 2025
·
1 min read
·
Dan Samorodnitsky
Layoff Tracker
Ferring To Cut 500 Employees as Part of Business Model Shift
Follow along as
BioSpace
tracks job cuts and restructuring initiatives.
October 10, 2025
·
70 min read
·
BioSpace Editorial Staff
BIOSECURE Act
The BIOSECURE Act Is Back, as Congress Tacks New Version On to Broader Defense Bill
A new version of the controversial bill removes the specific company names that were included in a previous iteration but still requires the industry to ditch Chinese biotech contractors in order to receive federal dollars.
October 10, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Therma Bright Appoints US Healthcare Veteran Michael Raimondo to the Board of Directors
October 10, 2025
·
4 min read
Press Releases
OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma
75% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p < 0.0001) 100% of patients who achieved 12 month event free survival achieved 2 year overall survival
October 10, 2025
·
6 min read
Mergers & acquisitions
BMS Makes $1.5B Cell Therapy Play With Orbital Takeover
Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they “continue to look for more” from Bristol Myers Squibb before they can “get excited about the near term turnaround story.”
October 10, 2025
·
2 min read
·
Tristan Manalac
1 of 86,012
Next
